@article{ATM19768,
author = {Jiawen Chen and Wei Yang and Zimu Gong},
title = {Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future},
journal = {Annals of Translational Medicine},
volume = {6},
number = {11},
year = {2018},
keywords = {},
abstract = {Recently, O’Connor et al. reported the high activity of the combination of brentuximab vedotin (BV) and bendamustine in relapsed/refractory Hodgkin’s lymphoma (HL) patients (1). The study is notable for the heavily treated population and relatively large sample size.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/19768}
}